Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Liabilities: 2014-2025

Historic Other Non-Current Liabilities for ImmunityBio (IBRX) over the last 8 years, with Sep 2025 value amounting to $115.2 million.

  • ImmunityBio's Other Non-Current Liabilities rose 499.07% to $115.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.2 million, marking a year-over-year increase of 499.07%. This contributed to the annual value of $26.1 million for FY2024, which is 78.01% down from last year.
  • ImmunityBio's Other Non-Current Liabilities amounted to $115.2 million in Q3 2025, which was up 71.99% from $67.0 million recorded in Q2 2025.
  • ImmunityBio's 5-year Other Non-Current Liabilities high stood at $118.8 million for Q4 2023, and its period low was $288,000 during Q1 2022.
  • In the last 3 years, ImmunityBio's Other Non-Current Liabilities had a median value of $39.4 million in 2023 and averaged $57.0 million.
  • As far as peak fluctuations go, ImmunityBio's Other Non-Current Liabilities spiked by 9,485.86% in 2023, and later slumped by 81.32% in 2025.
  • Over the past 5 years, ImmunityBio's Other Non-Current Liabilities (Quarterly) stood at $411,000 in 2021, then skyrocketed by 5,164.23% to $21.6 million in 2022, then spiked by 448.95% to $118.8 million in 2023, then tumbled by 78.01% to $26.1 million in 2024, then surged by 499.07% to $115.2 million in 2025.
  • Its last three reported values are $115.2 million in Q3 2025, $67.0 million for Q2 2025, and $20.5 million during Q1 2025.